3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
102
Carcinoma, Non-Small-Cell Lung
93
Multiple Myeloma
80
Prostatic Neoplasms
74
Colorectal Neoplasms
59
Neoplasms
57
Leukemia, Myeloid, Acute
56
Lymphoma
48
Squamous Cell Carcinoma of Head and Neck
43
Lung Neoplasms
39
Ovarian Neoplasms
38
Melanoma
38
Neoplasm Metastasis
36
Pancreatic Neoplasms
35
Lymphoma, Non-Hodgkin
35
Carcinoma, Hepatocellular
34
Lymphoma, Large B-Cell, Diffuse
33
Sarcoma
31
Head and Neck Neoplasms
31
Urinary Bladder Neoplasms
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Carcinoma, Renal Cell
29
Leukemia, Lymphocytic, Chronic, B-Cell
28
Hodgkin Disease
28
Endometrial Neoplasms
28
Triple Negative Breast Neoplasms
27
Myelodysplastic Syndromes
26
Recurrence
25
Hematologic Neoplasms
25
Glioma
25
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
von Hippel-Lindau Disease
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA